Brief: Enlivex Announces Regulatory Clearance In Multiple Countries For Integration Of Frozen Allocetra Formulation And Expansion Of Patient Population In Its Sepsis Phase II Clinical Trial

Enlivex

24/08/2022 13:07

Aug 24 (Reuters) - Enlivex Therapeutics Ltd  ENLV.TA :
    * ENLIVEX ANNOUNCES REGULATORY CLEARANCE IN MULTIPLE
COUNTRIES FOR
INTEGRATION OF FROZEN ALLOCETRA FORMULATION AND EXPANSION OF
PATIENT POPULATION IN ITS SEPSIS PHASE II CLINICAL TRIAL
    * ENLIVEX THERAPEUTICS LTD - SEPSIS PHASE II PROTOCOL
AMENDMENTS
HAVE BEEN CLEARED BY REGULATORY AUTHORITIES IN ISRAEL, SPAIN,
AND GREECE
    * ENLIVEX THERAPEUTICS LTD - PLANS TO OBTAIN CLEARANCES FOR
PROTOCOL AMENDMENTS IN ADDITIONAL JURISDICTIONS
    * ENLIVEX THERAPEUTICS LTD - SHELF LIFE OF FROZEN ALLOCETRA™
FORMULATION IS EXPECTED TO BE VASTLY SUPERIOR TO THAT OF ITS
LIQUID FORMULATION
    * ENLIVEX - EXPECTS BROAD ACCEPTANCE OF PROPOSED AMENDMENTS
WILL
SHORTEN TIMELINE FOR POTENTIAL REGULATORY APPROVAL OF FROZEN
ALLOCETRA FORMULATION
    * ENLIVEX - FROZEN FORMULATION OF ALLOCETRA EXPECTED TO HAVE
A
SHELF-LIFE SPANNING MULTIPLE YEARS, VERSUS SHELF LIFE OF 96
HOURS FOR LIQUID FORMULATION
    * ENLIVEX - EXTENDED SHELF LIFE EXPECTED TO DRAMATICALLY
IMPROVE
MANUFACTURING SCALABILITY AND SHIPPING LOGISTICS WHILE REDUCING
PRODUCTION COSTS

Source text for Eikon:  ID:nGNX6PDB4Y 
Further company coverage:  ENLV.TA 

 ((Reuters.Briefs@thomsonreuters.com;))